Evidence map›Paper›PMID 38699646›Full record

ArticleFrontiers in oncology2024

Rapid response to fifth-line brigatinib plus entrectinib in an

Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dan Li *Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Yue Zhu *Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Jincheng SongDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Dafu YangDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Saiqiong CuiDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Xin LiuDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Le WangDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Jiangyan ZhangDepartment of Medical Services, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Evenki PanDepartment of Medical Services, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Zhaoxia DaiDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (

Indexed as

ALK rearrangementbrigatinibentrectinibETV6-NTRK3resistance mutations

Identifiers

PMID38699646
PMCPMC11063249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.